Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations
| Autor: | Tamara Y. Milder, David A. Milder, Peter Kam |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Diabetic ketoacidosis business.industry 030209 endocrinology & metabolism Perioperative medicine.disease Ketoacidosis 03 medical and health sciences 0302 clinical medicine Anesthesiology and Pain Medicine medicine 030212 general & internal medicine Intensive care medicine business Oral hypoglycaemic |
| Zdroj: | Anaesthesia. 73:1008-1018 |
| ISSN: | 0003-2409 |
| DOI: | 10.1111/anae.14251 |
| Popis: | Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an emerging class of oral hypoglycaemic agents with therapeutic benefits beyond better glycaemic control. A major concern of the sodium-glucose co-transporter 2 inhibitors is their propensity to cause euglycaemic ketoacidosis in the peri-operative period and the potential for this critical diagnosis to be delayed or missed entirely. This review attempts to collate the case reports of sodium-glucose co-transporter 2 inhibitor ketoacidosis associated with surgery to highlight and put a perspective on this peri-operative issue. Preventive strategies and the management of the ketoacidosis are discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text